SB

Stephane Boissel

CEO

SparingVision

Paris, Ile-de-France


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
SparingVision
Industry
biotechnology
Employees
48.0
Seniority
C suite
Annual Revenue
3000000.0
Total Funding
148983220.0
Latest Funding
Series B

Technologies

Outlook Microsoft Office 365 reCAPTCHA Vimeo Mobile Friendly Nginx Google Maps Apache WordPress.org Google Font API Remote AI

Keywords

ocular diseases inherited retinal diseases irds gene therapy genomic medicines retinitis pigmentosa rp therapeutic innovation gene agnostic mutations photoreceptors cone viability factor anti-oxidative stress subretinal injection clinical-stage clinical trial mutation independent neuroprotective therapy aav-based delivery crispr/cas9 genome editing ocular drug discovery vision saving treatments progressive vision loss optical restoration blindness prevention patient outcomes dormant cones visual acuity restoration genetic mutation phototransduction cascade gene therapy approaches gene replacement genetic disorders advanced stage treatment biopharmaceutical pipeline treatment development safety data trials preliminary efficacy patient care optogenetics biological research genetic intervention therapeutic synergy long-term results active clinical research medical advancements therapy options retinal degeneration therapies combined therapy constructs

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans